James W Catto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8516026/publications.pdf

Version: 2024-02-01

290	20,981	13854 67	11047 137
papers	citations	h-index	g-index

320	320	320	20635
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 2016, 375, 1415-1424.	13.9	2,101
2	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	13.5	1,742
3	Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 2013, 63, 234-241.	0.9	1,572
4	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 2016, 375, 1425-1437.	13.9	962
5	Systematic Review of Complications of Prostate Biopsy. European Urology, 2013, 64, 876-892.	0.9	779
6	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. European Urology, 2018, 74, 784-795.	0.9	530
7	MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. European Urology, 2011, 59, 671-681.	0.9	401
8	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	372
9	Systematic Review and Cumulative Analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Cystectomy. European Urology, 2015, 67, 376-401.	0.9	364
10	Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, The, 2020, 395, 1268-1277.	6.3	311
11	Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. Cancer Research, 2009, 69, 8472-8481.	0.4	291
12	The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. European Urology, 2016, 70, 458-466.	0.9	285
13	Promoter Hypermethylation Is Associated With Tumor Location, Stage, and Subsequent Progression in Transitional Cell Carcinoma. Journal of Clinical Oncology, 2005, 23, 2903-2910.	0.8	273
14	Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. European Urology, 2020, 77, 663-666.	0.9	239
15	Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. European Urology, 2016, 70, 176-187.	0.9	230
16	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ: British Medical Journal, 2012, 344, d7894-d7894.	2.4	211
17	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. European Urology, 2015, 68, 238-253.	0.9	211
18	Repeat Transurethral Resection in Nonâ€“muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 2018, 73, 925-933.	0.9	209

#	Article	IF	Citations
19	Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 693-703.	0.9	207
20	The Mutational Landscape of Prostate Cancer. European Urology, 2013, 64, 567-576.	0.9	203
21	Systematic Review and Cumulative Analysis of Oncologic and Functional Outcomes After Robot-assisted Radical Cystectomy. European Urology, 2015, 67, 402-422.	0.9	199
22	Hexyl Aminolevulinateâ€“Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Nonâ€“Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. European Urology, 2013, 64, 624-638.	0.9	193
23	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	0.9	190
24	Epigenetics in Prostate Cancer: Biologic and Clinical Relevance. European Urology, 2011, 60, 753-766.	0.9	187
25	Contemporary Occupational Carcinogen Exposure and Bladder Cancer. JAMA Oncology, 2015, 1, 1282.	3.4	184
26	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. European Urology, 2020, 78, 402-414.	0.9	183
27	Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11. Clinical Cancer Research, 2014, 20, 1990-2000.	3.2	179
28	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	0.9	166
29	Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer. Clinical Cancer Research, 2007, 13, 2046-2053.	3.2	163
30	Best Practices in Robot-assisted Radical Cystectomy and Urinary Reconstruction: Recommendations of the Pasadena Consensus Panel. European Urology, 2015, 67, 363-375.	0.9	158
31	Behavior of Urothelial Carcinoma With Respect to Anatomical Location. Journal of Urology, 2007, 177, 1715-1720.	0.2	156
32	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	0.9	151
33	Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage. Clinical Cancer Research, 2007, 13, 1720-1725.	3.2	139
34	Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. European Urology, 2018, 73, 363-371.	0.9	139
35	Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Nonâ€“muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. European Urology, 2020, 77, 101-109.	0.9	139
36	Early Detection of Prostate Cancer: European Association of Urology Recommendation. European Urology, 2013, 64, 347-354.	0.9	133

#	Article	IF	Citations
37	Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene, 2003, 22, 8699-8706.	2.6	127
38	Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. European Urology, 2016, 70, 649-660.	0.9	114
39	Predicting Response to Intravesical Bacillus Calmette-GuÃ©rin Immunotherapy: Are We There Yet? A Systematic Review. European Urology, 2018, 73, 738-748.	0.9	112
40	iTRAQ-Facilitated Proteomic Analysis of Human Prostate Cancer Cells Identifies Proteins Associated with Progression. Journal of Proteome Research, 2008, 7, 897-907.	1.8	110
41	FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours. European Urology, 2009, 55, 650-658.	0.9	110
42	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. European Urology, 2020, 78, 29-42.	0.9	110
43	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. European Urology, 2021, 80, 703-711.	0.9	108
44	Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 2092.	3.8	108
45	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. European Urology, 2020, 77, 320-330.	0.9	107
46	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. European Urology, 2018, 74, 357-368.	0.9	105
47	Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. European Radiology, 2019, 29, 5498-5506.	2.3	104
48	Enhanced Recovery After Surgery: Are We Ready, and Can We Afford Not to Implement These Pathways for Patients Undergoing Radical Cystectomy?. European Urology, 2014, 65, 263-266.	0.9	102
49	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. European Urology, 2015, 67, 729-737.	0.9	100
50	Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncology, The, 2019, 20, 436-447.	5.1	100
51	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 306-315.	2.6	97
52	Hypermethylation of CpG Islands and Shores around Specific MicroRNAs and Mirtrons Is Associated with the Phenotype and Presence of Bladder Cancer. Clinical Cancer Research, 2011, 17, 1287-1296.	3.2	96
53	Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Review of Anticancer Therapy, 2012, 12, 271-281.	1.1	92
54	Application of Artificial Intelligence to the Management of Urological Cancer. Journal of Urology, 2007, 178, 1150-1156.	0.2	89

#	Article	IF	Citations
55	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open, 2018, 8, e022899.	0.8	85
56	An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. European Radiology, 2017, 27, 3759-3766.	2.3	81
57	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 142-150.	0.9	80
58	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. International Journal of Cancer, 2008, 122, 952-956.	2.3	77
59	Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. European Urology, 2021, 79, 621-632.	0.9	77
60	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. European Urology Oncology, 2019, 2, 265-273.	2.6	75
61	Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. International Journal of Cancer, 2003, 105, 484-490.	2.3	73
62	Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. Journal of Pathology, 2006, 209, 336-343.	2.1	73
63	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. European Urology, 2020, 78, 719-730.	0.9	73
64	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2014, 66, 628-632.	0.9	72
65	Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. European Urology, 2015, 67, 876-888.	0.9	72
66	Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. BMJ Open, 2018, 8, e020500.	0.8	71
67	Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. Clinical Cancer Research, 2003, 9, 4172-7.	3.2	71
68	Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. World Journal of Urology, 2013, 31, 21-29.	1.2	70
69	Precision surgery and genitourinary cancers. European Journal of Surgical Oncology, 2017, 43, 893-908.	0.5	70
70	Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Nonâ€“muscle-invasive Bladder Cancer. European Urology, 2013, 63, 145-154.	0.9	68
71	Treatment Options Available for Bacillus Calmette-GuÃ©rin Failure in Nonâ€“muscle-invasive Bladder Cancer. European Urology, 2012, 62, 1088-1096.	0.9	67
72	Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Human Pathology, 2004, 35, 1385-1391.	1.1	66

#	Article	IF	Citations
73	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. European Urology, 2020, 78, 209-220.	0.9	66
74	Regulation of Neutrophil Senescence by MicroRNAs. PLoS ONE, 2011, 6, e15810.	1.1	65
75	Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?. European Urology Focus, 2016, 2, 19-29.	1.6	65
76	Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. European Urology Focus, 2016, 2, 113-121.	1.6	65
77	Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives. European Urology, 2013, 63, 1049-1058.	0.9	64
78	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	0.9	61
79	Multifocal Urothelial Cancers With the Mutator Phenotype are of Monoclonal Origin and Require Panurothelial Treatment for Tumor Clearance. Journal of Urology, 2006, 175, 2323-2330.	0.2	58
80	Robot-assisted Radical Cystectomy and Urinary Diversion: Technical Recommendations from the Pasadena Consensus Panel. European Urology, 2015, 67, 423-431.	0.9	58
81	Telemedicine and Smart Working: Recommendations of the European Association of Urology. European Urology, 2020, 78, 812-819.	0.9	57
82	Luzp4 defines a new mRNA export pathway in cancer cells. Nucleic Acids Research, 2015, 43, 2353-2366.	6.5	56
83	Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate, 2007, 67, 1761-1769.	1.2	55
84	Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer. Clinical Cancer Research, 2014, 20, 5311-5321.	3.2	55
85	Health-related quality of life after treatment for bladder cancer in England. British Journal of Cancer, 2018, 118, 1518-1528.	2.9	55
86	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. European Urology Oncology, 2018, 1, 292-304.	2.6	54
87	The patientsâ€™ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence. Journal of Cancer Survivorship, 2017, 11, 453-461.	1.5	53
88	Online Professionalismâ€”2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2018, 74, 644-650.	0.9	53
89	Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. Journal of Clinical Oncology, 2021, 39, 202-214.	0.8	53
90	Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate, 2005, 65, 322-330.	1.2	52

#	Article	IF	Citations
91	The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression. European Urology, 2010, 57, 398-406.	0.9	52
92	Disease Specific Mortality in Patients with Low Risk Bladder Cancer and the Impact of Cystoscopic Surveillance. Journal of Urology, 2013, 189, 828-833.	0.2	50
93	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU International, 2008, 101, 1448-1453.	1.3	49
94	Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers, 2020, 12, 2994.	1.7	49
95	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 368-380.	0.9	48
96	BPH and prostate cancer risk. Indian Journal of Urology, 2014, 30, 214.	0.2	48
97	A miRNA-145/TGF-Î²1 negative feedback loop regulates the cancer-associated fibroblast phenotype. Carcinogenesis, 2018, 39, 798-807.	1.3	47
98	KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. American Journal of Pathology, 2011, 179, 540-546.	1.9	44
99	Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1078-1087.	0.8	42
100	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology, 2017, 71, 381-388.	0.9	41
101	Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. European Urology, 2022, 81, 157-167.	0.9	41
102	Social Media Offers Unprecedented Opportunities for Vibrant Exchange of Professional Ideas Across Continents. European Urology, 2014, 66, 118-119.	0.9	40
103	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. European Urology, 2020, 77, 583-598.	0.9	40
104	Markers for Detection of Prostate Cancer. Cancers, 2010, 2, 1125-1154.	1.7	39
105	Global epigenetic profiling in bladder cancer. Epigenomics, 2011, 3, 35-45.	1.0	39
106	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World Journal of Urology, 2017, 35, 355-365.	1.2	39
107	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. European Urology, 2020, 78, 731-742.	0.9	39
108	The longâ€term outcome of treated highâ€risk nonmuscleâ€invasive bladder cancer. Cancer, 2012, 118, 5525-5534.	2.0	38

#	Article	IF	Citations
109	Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors. European Urology, 2016, 69, 183-185.	0.9	38
110	Long-term Outcomes from Re-resection for High-risk Nonâ€“muscle-invasive Bladder Cancer: A Potential to Rationalize Use. European Urology Focus, 2019, 5, 650-657.	1.6	38
111	Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. European Urology, 2021, 80, 12-15.	0.9	38
112	Integrated Epigenome Profiling of Repressive Histone Modifications, DNA Methylation and Gene Expression in Normal and Malignant Urothelial Cells. PLoS ONE, 2012, 7, e32750.	1.1	34
113	Evaluating patientâ€reported outcome measures (<scp>PROM</scp>s) for bladder cancer: a systematic review using the <scp>CO</scp>nsensusâ€based Standards for the selection of health Measurement INstruments (<scp>COSMIN</scp>) checklist. BJU International, 2018, 122, 760-773.	1.3	34
114	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	0.9	34
115	Next-generation RNA Sequencing of Archival Formalin-fixed Paraffin-embedded Urothelial Bladder Cancer. European Urology, 2014, 66, 982-986.	0.9	33
116	Survey of the Impact of COVID-19 on Oncologistsâ€™ Decision Making in Cancer. JCO Global Oncology, 2020, 6, 1248-1257.	0.8	33
117	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Health Technology Assessment, 2018, 22, 1-96.	1.3	33
118	Neuro-Fuzzy Modeling: An Accurate and Interpretable Method for Predicting Bladder Cancer Progression. Journal of Urology, 2006, 175, 474-479.	0.2	32
119	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU International, 2020, 125, 506-514.	1.3	32
120	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer â€“ a multicentre observational study. BJU International, 2021, 128, 440-450.	1.3	30
121	Low Frequency of Epigenetic Events in Urothelial Tumors in Young Patients. Journal of Urology, 2010, 184, 459-463.	0.2	28
122	VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic. European Urology, 2020, 78, e18-e20.	0.9	28
123	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycinâ€C vs surgical management in lowâ€risk nonâ€muscleâ€invasive bladder cancer. BJU International, 2020, 125, 817-826.	1.3	27
124	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		27
125	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. European Urology Oncology, 2021, 4, 12-19.	2.6	26
126	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. Annals of Oncology, 2015, 26, 2392-2398.	0.6	25

#	Article	IF	Citations
127	Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. BMJ Open, 2017, 7, e017913.	0.8	25
128	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 2018, 99, 75-83.	2.4	25
129	Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder. Clinical Cancer Research, 2009, 15, 3150-3155.	3.2	24
130	Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients. European Urology, 2018, 74, 531-534.	0.9	24
131	MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. Oncotarget, 2014, 5, 6375-6386.	0.8	23
132	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	23
133	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 2020, 38, 1959-1968.	1.2	22
134	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	1.3	22
135	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patientâ€™s undergoing urologic oncology surgery: a systematic review. World Journal of Urology, 2022, 40, 1325-1342.	1.2	21
136	Epigenetic Regulation of MicroRNA Expression in Cancer. Methods in Molecular Biology, 2011, 676, 165-184.	0.4	21
137	SIMULTANEOUS AUGMENTATION CYSTOPLASTY IS ASSOCIATED WITH EARLIER RATHER THAN INCREASED ARTIFICIAL URINARY SPHINCTER INFECTION. Journal of Urology, 2005, 173, 1237-1241.	0.2	20
138	Challenging current paradigms. Nature Reviews Urology, 2013, 10, 67-68.	1.9	20
139	A New Fuzzy Modeling Framework for Integrated Risk Prognosis and Therapy of Bladder Cancer Patients. IEEE Transactions on Fuzzy Systems, 2018, 26, 1565-1577.	6.5	20
140	Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study. European Urology, 2008, 53, 777-784.	0.9	19
141	Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?. European Urology, 2015, 68, 1-2.	0.9	19
142	Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy. Oncotarget, 2016, 7, 76140-76150.	0.8	19
143	Molecular subtyping of bladder cancer using <scp>K</scp>ohonen selfâ€organizing maps. Cancer Medicine, 2014, 3, 1225-1234.	1.3	18
144	The Problem Is Not What to Do with Indolent and Harmless Prostate Cancerâ€”The Problem Is How to Avoid Finding These Cancers. European Urology, 2016, 70, 547-548.	0.9	18

#	Article	IF	Citations
145	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	0.9	18
146	Urinary, bowel and sexual health in older men from Northern Ireland. BJU International, 2018, 122, 845-857.	1.3	18
147	Should We Perform Multiparametric Magnetic Resonance Imaging of the Bladder Before Transurethral Resection of Bladder? Time to Reconsider the Rules. European Urology, 2019, 76, 57-58.	0.9	18
148	Specificity of the Metallothionein-1 Response by Cadmium-Exposed Normal Human Urothelial Cells. International Journal of Molecular Sciences, 2019, 20, 1344.	1.8	18
149	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. European Urology Focus, 2020, 6, 1226-1232.	1.6	18
150	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. BJU International, 2018, 122, 970-977.	1.3	17
151	Bladder-sparing treatment in MIBC: where do we stand?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 101-112.	3.9	17
152	DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. Prostate, 2007, 67, 341-347.	1.2	16
153	Snapshot of transurethral resection of bladder tumours in the <scp>U</scp>nited <scp>K</scp>ingdom Audit (<scp>STUKA</scp>). BJU International, 2013, 112, 930-935.	1.3	16
154	Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. European Urology, 2016, 70, 1.	0.9	16
155	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology, 2018, 96, 35-46.	2.4	16
156	Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence. European Urology Focus, 2018, 4, 725-730.	1.6	16
157	EORTC risk tables â€“ their usefulness in the assessment of recurrence and progression risk in nonâ€“muscleâ€“invasive bladder cancer in Polish patients. Urologia Polska, 2013, 65, 14-20.	0.5	16
158	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 650-658.	5.1	16
159	The contemporary landscape of occupational bladder cancer within the United Kingdom: a metaâ€analysis of risks over the last 80 years. BJU International, 2017, 119, 100-109.	1.3	15
160	E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks. European Urology, 2017, 71, 915-923.	0.9	15
161	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer, 2020, 123, 1063-1070.	2.9	15
162	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clinical Cancer Research, 2021, 27, 1882-1892.	3.2	15

#	Article	IF	Citations
163	Occupational exposure to crack detection dye penetrants and the potential for bladder cancer: Table 1. Occupational and Environmental Medicine, 2012, 69, 300.2-301.	1.3	14
164	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. PLoS ONE, 2020, 15, e0239338.	1.1	14
165	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 837-855.	1.9	14
166	Clinically localised prostate cancer is microsatellite stable. BJU International, 2007, 99, 1031-1035.	1.3	13
167	Changing Current Practice in Urology: Improving Guideline Development and Implementation Through Stakeholder Engagement. European Urology, 2017, 72, 161-163.	0.9	13
168	Noncoding RNA in bladder cancer. Current Opinion in Urology, 2014, 24, 506-511.	0.9	12
169	A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).. Journal of Clinical Oncology, 2022, 40, TPS579-TPS579.	0.8	12
170	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 117, 849-849.	1.3	11
171	Radical Cystectomy in England from 2013 to 2019 on 12,644 patients: An analysis of national trends and comparison of surgical approaches using Hospital Episode Statistics data. BJUI Compass, 2021, 2, 338-347.	0.7	11
172	The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. European Urology, 2021, 80, 450-453.	0.9	11
173	Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology. European Urology, 2022, , .	0.9	11
174	Whole-body Magnetic Resonance Imaging and Prostate Cancer Metastases: A New Gold Standard of Detection, But Does It Help Us and At What Cost?. European Urology, 2012, 62, 76-77.	0.9	10
175	Identification and Diagnostic Performance of a Small RNA within the PCA3 and BMCC1 Gene Locus That Potentially Targets mRNA. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 268-275.	1.1	10
176	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. European Urology Focus, 2015, 1, 82-89.	1.6	10
177	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 118, E1-2.	1.3	10
178	A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-GuÃ©rin (BCG) therapy.. Journal of Clinical Oncology, 2020, 38, TPS603-TPS603.	0.8	10
179	Pancreatic debridement in a district general hospital â€“ viable or vulnerable?. Annals of the Royal College of Surgeons of England, 2002, 84, 309-313.	0.3	10
180	More Nomograms or Better Evidence of Efficacy: What Do We Need in Urologic Oncology?. European Urology, 2008, 54, 11-12.	0.9	9

#	Article	IF	Citations
181	Prostate cancer proteomics: The urgent need for clinically validated biomarkers. Proteomics - Clinical Applications, 2009, 3, 197-212.	0.8	9
182	Predictive modeling in cancer: where systems biology meets the stock market. Expert Review of Anticancer Therapy, 2009, 9, 867-870.	1.1	9
183	New Gleason grading system: Statement from the Editors of six journals. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 253.	0.8	9
184	Stage Grouping. Journal of Urology, 2016, 195, 1723-1723.	0.2	9
185	Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology, 2016, 93, 1.	0.5	9
186	Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers. European Urology Oncology, 2020, 3, 548-554.	2.6	9
187	Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 265-278.	3.9	9
188	The Road to Cystectomy: Who, When and Why?. EAU Update Series, 2005, 3, 118-128.	0.5	8
189	Robotic intracorporeal urinary diversion: practical review of current surgical techniques. Minerva Urology and Nephrology, 2016, 69, 14-25.	1.3	8
190	Comparing open-radical cystectomy and robot-assisted radical cystectomy. Current Opinion in Urology, 2020, 30, 400-406.	0.9	8
191	Gastrointestinal Toxicity Following Radiotherapy for Prostate Cancer: A Ring of Fire. European Urology, 2011, 60, 917-919.	0.9	7
192	MicroRNA in Prostate Cancer: An Opportunity to Individualize Patient Care. Journal of Urology, 2012, 187, 1155-1156.	0.2	7
193	SPIRE â€“ combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. Trials, 2018, 19, 216.	0.7	7
194	Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294â€“306. European Urology, 2018, 74, e109.	0.9	7
195	A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 811-820.	1.2	7
196	Islam and the Urinary Stoma: A Contemporary Theological and Urological Dilemma. European Urology Focus, 2019, 5, 301-305.	1.6	7
197	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. BMJ Open, 2020, 10, e036024.	0.8	7
198	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. European Urology Focus, 2020, 7, 554-565.	1.6	7

#	Article	IF	Citations
199	The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is â€œSafe Better than Sorryâ€?. European Urology, 2020, 78, 134-135.	0.9	7
200	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. European Urology Open Science, 2021, 33, 1-10.	0.2	7
201	Gene of the month: NKX3.1. Journal of Clinical Pathology, 2022, 75, 361-364.	1.0	7
202	Less is more: artificial intelligence and gene-expression arrays. Lancet, The, 2004, 364, 2003-2004.	6.3	6
203	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. Journal of Clinical Epidemiology, 2019, 113, 200-213.	2.4	6
204	Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. European Urology, 2019, 76, 228-237.	0.9	6
205	Life and bladder cancer: protocol for a longitudinal and cross-sectional patient-reported outcomes study of Yorkshire (UK) patients. BMJ Open, 2019, 9, e030850.	0.8	6
206	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. International Journal of Surgery Protocols, 2020, 21, 8-12.	0.5	6
207	The Use of Proteomics in Urological Research. EAU Update Series, 2005, 3, 171-179.	0.5	5
208	The Changing Face of Renal Cell Carcinoma: The Impact of Systematic Genetic Sequencing on Our Understanding of This Tumor's Biology. European Urology, 2013, 63, 855-857.	0.9	5
209	Reply to Mark C. Kendall's Letter to the Editor re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363â€“71. European Urology, 2018, 74, e66.	0.9	5
210	Impact of Anaesthetist Volume on Radical Cystectomy Outcomes. European Urology Focus, 2021, 7, 117-123.	1.6	5
211	The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project. European Urology Focus, 2021, 7, 905-908.	1.6	5
212	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Nonâ€“muscle-invasive Bladder Cancer. European Urology Oncology, 2022, 5, 70-83.	2.6	5
213	In Defense of Randomized Clinical Trials in Surgery: Let Us Not Forget Archie Cochrane's Legacy. European Urology, 2017, 71, 820-821.	0.9	4
214	Is Social Media Worth the Risk for Health Care Professionals?. European Urology Focus, 2020, 6, 427-429.	1.6	4
215	Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath study.. Journal of Clinical Oncology, 2020, 38, 446-446.	0.8	4
216	Old and New Urinary Markers: Which One is the PSA for Bladder Cancer?. European Urology Supplements, 2008, 7, 422-425.	0.1	3

#	Article	IF	Citations
217	European Urology: Quality, Impact, Online. European Urology, 2013, 64, 523-524.	0.9	3
218	Micro<scp>RNA</scp> and urothelial cell carcinoma. BJU International, 2014, 113, 811-812.	1.3	3
219	Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294â€“306. European Urology, 2019, 75, e29-e30.	0.9	3
220	Does the robot have a role in radical cystectomy?. BJU International, 2019, 123, 380-382.	1.3	3
221	Innovations in Statistical Review at European Urology. European Urology, 2019, 75, 1-2.	0.9	3
222	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	0.9	3
223	Measuring Patient Compliance With Remote Monitoring Following Discharge From Hospital After Major Surgery (DREAMPath): Protocol for a Prospective Observational Study. JMIR Research Protocols, 2022, 11, e30638.	0.5	3
224	The development of the Cystectomyâ€Pathway Assessment Tool (Câ€PAT): a concise tool to assess the quality of care in the cystectomy pathway. BJU International, 2022, 129, 708-717.	1.3	3
225	Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers. , 2015, , 1-30.		3
226	Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. Journal of Clinical Oncology, 2020, 38, e17057-e17057.	0.8	3
227	The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?. Journal of Molecular Medicine, 2006, 84, 883-885.	1.7	2
228	TIME TO CHANGE OUR APPROACH TO HIGHâ€RISK NONMUSCLEâ€INVASIVE BLADDER CANCER MANAGEMENT IN THE UNITED KINGDOM? OBSERVATIONS FROM THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS CANCER REGISTRY. BJU International, 2010, 106, 593-594.	1.3	2
229	The Quest for an Optimal Definition of Prostate-specific Antigen Failure Following Radical Prostatectomy: The Risk of Not Seeing the Forest for the Trees. European Urology, 2014, 66, 211-213.	0.9	2
230	Exercise interventions for men with prostate cancer. The Cochrane Library, 0, , .	1.5	2
231	Reply to Wentao Liu, Xiaokun Zhao, Zhaohui Zhong's Letter to the Editor re: Marcus G. Cumberbatch, Matteo Rota, James W.F. Catto, Carlo La Vecchia. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol 2016;70:458â€“66. European Urology, 2016, 70, e106-e107.	0.9	2
232	Reducing Complications After Surgery: Still a Long Way To Go. European Urology Focus, 2016, 2, 1-2.	1.6	2
233	Editorial Statement on Gleason Scoring for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1092.	0.4	2
234	Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. Urology Practice, 2017, 4, 349-354.	0.2	2

#	Article	IF	Citations
235	Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. PLoS ONE, 2017, 12, e0175070.	1.1	2
236	Improving Standards of Care through the Publication of Surgeon Identifiable Outcome Data in Urology. European Urology, 2018, 74, 1-3.	0.9	2
237	Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer. European Urology, 2018, 73, 479-480.	0.9	2
238	Robot-assisted versus open cystectomy in the RAZOR trial. Lancet, The, 2019, 393, 644-645.	6.3	2
239	Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valiottoâ€™s Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.039.	0.9	2
240	Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumasâ€™s Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Nonâ€“muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101â€“9. European Urology, 2020, 77, e94-e95.	0.9	2
241	Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?. European Urology, 2021, 80, 18-19.	0.9	2
242	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostateâ€"A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS385-TPS385.	0.8	2
243	Social deprivation and bladder cancer: cause or effect for disparities in survival for affected women. BJU International, 2022, 130, 301-302.	1.3	2
244	Investigation of haematuria. Foundation Years, 2006, 2, 80-82.	0.0	1
245	Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center: In Regard to Kotwal et al. (Int J Radiat) Tj ETQq1 1 0.784314 rgBT /Ov 71, 1601-1602.	0.4	1
246	Haematuria. Surgery, 2008, 26, 150-153.	0.1	1
247	Haematuria. Surgery, 2010, 28, 589-593.	0.1	1
248	Targeting chemotherapy to advanced bladder cancer patients most likely to benefit. Future Oncology, 2010, 6, 193-196.	1.1	1
249	Re: Comorbidity and Mortality Results from a Randomised Prostate Cancer Screening Trial. European Urology, 2011, 60, 867.	0.9	1
250	The Future of Prostate Cancer Diagnosis: Biomarkers, Biopsy, Both, or Neither?. European Urology Focus, 2015, 1, 97-98.	1.6	1
251	There Are Cooler Ways to Die Than Smoking: Urologists of the World, Unite Against This Health Care Tragedy. European Urology Focus, 2015, 1, 1-2.	1.6	1
252	Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. European Urology, 2019, 76, 872-873.	0.9	1

#	Article	IF	Citations
253	How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?. European Urology Oncology, 2019, 4, 663-669.	2.6	1
254	Urethral recurrence after radical cystoprostatectomy: Experience from a high-volume tertiary referral centre. Journal of Clinical Urology, 2021, 14, 238-245.	0.1	1
255	PD51-11â€ƒREPORTING RADICAL CYSTECTOMY OUTCOMES FOLLOWING IMPLEMENTATION OF ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOLS. Journal of Urology, 2020, 203, e1087-e1088.	0.2	1
256	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€”A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 2022, 40, TPS5103-TPS5103.	0.8	1
257	The Role of Genetic Instability in the Pathogenesis and Progression of Urothelial Carcinoma. EAU Update Series, 2005, 3, 180-188.	0.5	0
258	Assessing the patient with a urological problem. Foundation Years, 2005, 1, 1-7.	0.0	0
259	Urological diagnosis â€“ history and investigations. Surgery, 2008, 26, 154-160.	0.1	0
260	Re: Sequence Variant on 8q24 Confers Susceptibility to Urinary Bladder Cancer. European Urology, 2009, 55, 1487-1488.	0.9	0
261	The epigenetic profile of bladder cancer. , 0, , 323-337.		0
262	In Memory of John Fitzpatrick. European Urology, 2014, 66, 604.	0.9	0
263	European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. European Urology, 2015, 67, 188-190.	0.9	0
264	In Reply to Samaratunga etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1127-1128.	0.4	0
265	Micropapillary Variant Bladder Cancer: A Bad Apple or a New Fruit?. European Urology, 2016, 70, 621-622.	0.9	0
266	Adrenal Lesions: Progress on All Fronts. European Urology Focus, 2016, 1, 215-216.	1.6	0
267	Beware of Bugs! Hot Issues in Urinary Tract Infections and Inflammation. European Urology Focus, 2016, 2, 339-340.	1.6	0
268	The Use of Biomarkers to Manage Men with Metastatic Prostate Cancer: One Day, But Not Yet. European Urology Focus, 2016, 2, 467-468.	1.6	0
269	Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology, 2016, 96, 179.	0.5	0
270	Urinary Incontinence: Moving the Field Forward. European Urology Focus, 2016, 2, 229-230.	1.6	0

#	Article	IF	Citations
271	Kidney Cancer: Many Important Advances but Still a Lot to Debate. European Urology Focus, 2016, 2, 565-566.	1.6	0
272	The Rapidly Evolving Role of Imaging in Urology: How to Balance Breakthroughs in Knowledge with Overuse. European Urology Focus, 2016, 2, 111-112.	1.6	0
273	Speeding up recovery from radical cystectomy: how low can we go?. BJU International, 2017, 120, 162-163.	1.3	0
274	Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. European Urology, 2017, 71, e54.	0.9	0
275	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. Trials, 2018, 19, .	0.7	0
276	Reply from Authors re: Peter Albers. Volume Matters: Can We Rely on the Evidence? Eur Urol Oncol 2019;2:274â€“5. European Urology Oncology, 2019, 2, 276.	2.6	0
277	Open Science and Open Publishing: A New Paradigm for the European Urology Family. European Urology Open Science, 2020, 19, 1-2.	0.2	0
278	DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma.. Journal of Clinical Oncology, 2021, 39, 447-447.	0.8	0
279	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€"A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 2021, 39, TPS266-TPS266.	0.8	0
280	High Dimensionality and Scaling-up Performance of RBF Models with Application to Healthcare Informatics. International Journal of Machine Learning and Computing, 2015, 5, 62-67.	0.8	0
281	How Do I Publish a Scientific Urological Paper?. , 2017, , 323-329.		0
282	Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS3170-TPS3170.	0.8	0
283	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 2022, 40, TPS284-TPS284.	0.8	0
284	Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. Journal of Clinical Oncology, 2022, 40, 461-461.	0.8	0
285	Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041. European Urology, 2022, 82, e12-e12.	0.9	0
286	Title is missing!. , 2020, 15, e0239338.		0
287	Title is missing!. , 2020, 15, e0239338.		0
288	Title is missing!. , 2020, 15, e0239338.		0

#	Article	IF	Citations
289	Title is missing!. , 2020, 15, e0239338.		0
290	Case of the month from the University of Sheffield, <scp>UK</scp> : Expediting definitive treatment in patients with invasive bladder cancer: an <scp>MRI</scp> â€guided pathway. BJU International, 2022, 129, 691-694.	1.3	0